Skip to content

Frequency and Risk Factors for Autoimmune Disorders and Rheumatic Manifestations in Egyptian Patients With IBD

Frequency and Risk Factors for Autoimmune Disorders and Rheumatic Manifestations in Egyptian Patients With Inflammatory Bowel Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05771363
Enrollment
51
Registered
2023-03-16
Start date
2023-04-01
Completion date
2024-06-01
Last updated
2023-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IBD

Brief summary

To examine the prevelance of autoimmune disorders and rheumatic manifestations in egyptian patients with inflammatory bowel diseases,and asses the relation between prevelance of autoimmune disorders ,rheumatic manifestations and disease activity of IBD

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* 1-adult patients with adiagnosis of IBD according to the validated criteria. 2-patients\>18 years without aprevious diagnosis of SPA or other rheumatological manifestations.

Exclusion criteria

* 1- patients with active cancer or lymphoproliferative disease. 2-patients with uncontrolled diabetes. 3-patients with unstable ischeamic heart disease or congestive heart failure. 4-patients with acute renal failure. 5-patients already diagnosed with inflammatory or crystal induced arthropathies (including gout and calcium pyrophosphate dehydrate deposition disease) or other autoimmune diseases.

Design outcomes

Primary

MeasureTime frameDescription
frequency and risk factors for autoimmune disorders and rheumatic manifestations in Egyptian patients with inflammatory bowel diseases.1yearto examine the prevelance of autoimmune disorders and rheumatological manifestations in Egyptian patients with inflammatory bowel diseases

Contacts

Primary Contactamaal fathi, master
www.amalfathi1995@gmail.com01096585141

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026